Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Slim Fourati

Showing results (41-50 of 185) with videos related to

Pageof 19
Sort By:
JAMA Network Open|September 26, 2025
Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant RecipientsRabah Redjoul, Christine Robin, Laurent Softic, et al.
The Lancet. Infectious Diseases|October 12, 2024
Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitisSylvie Pillet, Aymeric Cantais, Blandine Noailly, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 9, 2025
How to manage antivirals in critically ill patients with influenza?Pierre Bay, Ignacio Martin-Loeches, Anne-Fleur Haudebourg, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2014
Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cureRuxandra Calin, Slim Fourati, Luminita Schneider, et al.
AIDS (London, England)|August 24, 2010
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretroviralsSlim Fourati, Isabelle Malet, Mawuena Binka, et al.
AIDS (London, England)|December 9, 2010
Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 yearsCathia Soulie, Sidonie Lambert-Niclot, Marc Wirden, et al.
Transplantation|June 17, 2025
BKPyV-specific T-cell Exhaustion in Kidney Transplant Recipients: Targeting Inhibitory Receptors Improves Their FunctionalityKaren Bargiel, Ivan Scriabine, Florence Herr, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2010
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonistsCathia Soulié, Slim Fourati, Sidonie Lambert-Niclot, et al.
The Journal of Infectious Diseases|November 5, 2023
Clinical Phenotypes and Molecular Characteristics of Respiratory Syncytial Virus in Adults: A Monocentric Prospective Study Between 2019 and 2022Pierre Bay, Cloé Loegel, Arnaud Ly, et al.
The Journal of Antimicrobial Chemotherapy|February 12, 2013
Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype BCathia Soulié, Sidonie Lambert-Niclot, Djenaba Bocar Fofana, et al.
Pageof 19

Showing results (41-50 of 185) with videos related to

Sort By:
Pageof 19
JAMA Network Open|September 26, 2025
Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant RecipientsRabah Redjoul, Christine Robin, Laurent Softic, et al.
The Lancet. Infectious Diseases|October 12, 2024
Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitisSylvie Pillet, Aymeric Cantais, Blandine Noailly, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 9, 2025
How to manage antivirals in critically ill patients with influenza?Pierre Bay, Ignacio Martin-Loeches, Anne-Fleur Haudebourg, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2014
Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cureRuxandra Calin, Slim Fourati, Luminita Schneider, et al.
AIDS (London, England)|August 24, 2010
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretroviralsSlim Fourati, Isabelle Malet, Mawuena Binka, et al.
AIDS (London, England)|December 9, 2010
Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 yearsCathia Soulie, Sidonie Lambert-Niclot, Marc Wirden, et al.
Transplantation|June 17, 2025
BKPyV-specific T-cell Exhaustion in Kidney Transplant Recipients: Targeting Inhibitory Receptors Improves Their FunctionalityKaren Bargiel, Ivan Scriabine, Florence Herr, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2010
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonistsCathia Soulié, Slim Fourati, Sidonie Lambert-Niclot, et al.
The Journal of Infectious Diseases|November 5, 2023
Clinical Phenotypes and Molecular Characteristics of Respiratory Syncytial Virus in Adults: A Monocentric Prospective Study Between 2019 and 2022Pierre Bay, Cloé Loegel, Arnaud Ly, et al.
The Journal of Antimicrobial Chemotherapy|February 12, 2013
Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype BCathia Soulié, Sidonie Lambert-Niclot, Djenaba Bocar Fofana, et al.
Pageof 19